Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better?


avatar Behnam Hashemi 1 , avatar Mitra Mahdavi-Mazdeh 2 , * , avatar Mohammadreza Abbasi 1 , avatar Seyed Mohammadmehdi Hosseini-Moghaddam 1 , avatar Nadia Hatmi Zinat 1 , avatar Farrokhlagh Ahmadi 1

Public Relations, Tehran University of Medical Sciences, IR Iran
1) Research Center of Iranian Tissue Bank, Tehran University of Medical Sciences. 2) Research Center of Nephrology, Tehran University of Medical Sciences, mmahdavi@sina.tums.ac.ir, IR Iran

how to cite: Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam S, Hatmi Zinat N, et al. Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better?. Hepat Mon. 2011;11(10): 816-820. https://doi.org/10.5812/kowsar.1735143X.751.


Background: Despite improvement in hepatitis B infection prevention through national vaccination programs, implementation of compulsory and thorough blood donor screening, and reduction of transfusion numbers due to erythropoietin administration, hepatitis B remains a major concern in hemodialysis (HD) centers (1). Compared to a response rate of over 90% in the normal population, only 50 to 60% of those with end-stage renal disease (ESRD) achieve protective antibody levels following immunization against hepatitis B (2, 3). Various strategies have been developed to overcome the low seroconversion rate in ESRD patients, including co-administering zinc, gamma-interferon, thymopentin, interleukin-2, and levamisole as immunostimulants or adjuvants (3, 4), changing the injection mode (intradermal versus intramuscular), or doubling the vaccine dose (5).
Objectives: Previous studies demonstrated that renal failure patients benefit from HBV vaccination; however, not all studies have demonstrated this. Therefore, we compared the rates of seroconversion (hepatitis B surface antibody [HBsAb] titer > 10 IU/mL) in patients at various stages of chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2) who received HBV vaccination.
Patients and Methods: A total of 167 patients in 3 different stages of CKD were vaccinated against HBV. Each patient received the vaccine according to a standardized vaccination schedule consisting of 40 μg of the recombinant vaccine "Engerix" at 0, 1, and 6 months. Eight to 12 weeks after the last dose of vaccination, anti-HBsAb levels were measured.
Results: Mean age and eGFR were 57.4 ± 16.5 years and 26.7 ± 14.7 mL/min/1.73 m2, respectively. The overall seroconversion rate was 78%. Although a significant correlation between HBsAb titer and eGFR (r = 0.265, P = 0.001) was observed, in the multivariate analysis using age, CKD stage, diabetes mellitus, and gender as independent variables, the degree of renal function did not significantly contribute to seroconversion. In contrast, higher age (> 60 years) showed a significant negative correlation to seroconversion (odds ratio = 0.22; P = 0.004).
Conclousions: CKD patients of advanced age should be vaccinated against HBV. Although higher eGFR was not associated with improved seroconversion, the persistence of seroconversion was not evaluated; future studies should be conducted to develop recommendations for earlier or later vaccination.

  • Implication for health policy/practice/research/medical education:
    Old CKD patients should have HBV Vaccination as soon as possible which may not be true for younger ones.
  • Please cite this paper as:
    Mahdavi-Mazdeh M, Hosseini-Moghaddam SM, Abbasi M, Hatmi Zinat N, Ahmadi F. Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better? Hepat Mon. 2011;11(10):816-20.

© 2011 Kowsar M.P.Co. All rights reserved.

Full Text

Full text is available in PDF